Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
Key Highlights
- ➤Q3 2026 financial results scheduled for release after market close November 5
- ➤Management webcast and conference call set for 4:30 p.m. Eastern Standard Time
- ➤REVTORPYK received FDA approval for eligible HR+/HER2- advanced breast cancer patients
- ➤VIKTORIA-2 Phase 3 trial remains ongoing across endocrine-resistant and endocrine-sensitive cohorts
- ➤CELC-G-201 Phase 1b/2 trial continues evaluating gedatolisib in metastatic castration-resistant prostate cancer
MINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the third quarter 2026 after the market closes on Thursday, November 5, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Standard Time to discuss the results and provide a corporate update.
To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1778641&tp_key=e66abcfe8a. A replay of the webcast will be available on the Celcuity website following the live event.
Get started
Create a free account to read the full story.